Free Trial
NASDAQ:XOMA

XOMA Royalty Q1 2026 Earnings Report

XOMA Royalty logo
$41.72 +0.03 (+0.06%)
Closing price 03:59 PM Eastern
Extended Trading
$41.69 -0.04 (-0.08%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

XOMA Royalty EPS Results

Actual EPS
$0.17
Consensus EPS
$0.19
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

XOMA Royalty Revenue Results

Actual Revenue
$12.32 million
Expected Revenue
$13.91 million
Beat/Miss
Missed by -$1.59 million
YoY Revenue Growth
N/A

XOMA Royalty Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

XOMA Royalty's Q2 2026 earnings is estimated for Thursday, July 30, 2026, based on past reporting schedules

Earnings Documents

XOMA Royalty Earnings Headlines

Saying Goodbye To The XOMA Royalty PFDs
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More XOMA Royalty Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA Royalty? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA Royalty and other key companies, straight to your email.

About XOMA Royalty

XOMA Royalty (NASDAQ:XOMA) (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways.

Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.

View XOMA Royalty Profile